Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II monalizumab after haploidentical HSCT with post-transplant cyclophosphamide in AML/MDS
2024-516974-31-00Phase 2Authorised
- Sponsor
- Humanitas Research Hospital
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of monalizumab in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by Humanitas Research Hospital. Primary endpoint: Graft-versus-host disease, progression or relapse, and survival (GPFS). Planned start Oct 2024; status: authorised.
02
Drugs
monalizumab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on 2024-516974-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516974-31-00.